Liquidia Q2 net loss $27.9M; court rulings clear legal path for YUTREPIA approval

Liquidia Corp

2024-Q2 EPS reported -$0.91 revenue$6,631,000

Q2 net loss $27.9M ($0.37/share) vs $23.5M ($0.36/share) in Q2 2023.
Revenue from Sandoz promotion $3.7M, down from $4.8M due to lower sales volumes.
Cash and equivalents $133.1M at June 30, 2024, up from $83.7M at Dec 31, 2023.
Court denied UTHR's preliminary injunction on YUTREPIA patent '327 on May 31; D.C. court also denied TRO/PI against FDA.
R&D expense fell 47% to $9.4M (no prior-year license fee); G&A rose 116% to $20.0M on sales force and legal costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.